dalteparin has been researched along with Complications, Pregnancy in 55 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Between August 1 2000 and June 20 2007, 116 pregnant women with: (i) | 9.14 | Dalteparin for the prevention of recurrence of placental-mediated complications of pregnancy in women without thrombophilia: a pilot randomized controlled trial. ( David, M; Demers, C; Garneau, P; Gauthier, R; Kahn, SR; Leduc, L; Magee, LA; Michon, N; Morin, F; Rey, E; Rodger, M, 2009) |
| "The present study suggests that pravastatin may improve pregnancy outcomes in women with refractory obstetric APS when taken at the onset of PE or IUGR until the end of pregnancy." | 7.83 | Pravastatin improves pregnancy outcomes in obstetric antiphospholipid syndrome refractory to antithrombotic therapy. ( Dagklis, T; Girardi, G; Lefkou, E; Mamopoulos, A; Rousso, D; Vosnakis, C, 2016) |
| "The aim of this retrospective, observational study was to determine the impact of low-dose enoxaparin (20 mg) in conjunction with low-dose aspirin on the pregnancy outcome of women with antiphospholipid syndrome and recurrent miscarriage." | 7.75 | Treatment of recurrent miscarriage and antiphospholipid syndrome with low-dose enoxaparin and aspirin. ( Li, TC; Makris, M; Metwally, M; Mo, D; Saravelos, S, 2009) |
| "Dalteparin sodium injection in patients with an immunologic component to RPL resulted in an increase in compliance without any adverse early pregnancy outcomes." | 7.70 | Dalteparin sodium injection treatment in patients with immunologic recurrent pregnancy loss. ( Trott, AM; Trott, EA, 2000) |
| "To determine whether low molecular weight heparin (LMWH) plus low-dose aspirin (LDA) is comparable in efficacy and safety to unfractionated heparin (UFH) plus LDA in the management of pregnant women with a history of recurrent spontaneous abortion secondary to antiphospholipid syndrome (APS)." | 5.15 | Enoxaparin versus unfractionated heparin in the management of recurrent abortion secondary to antiphospholipid syndrome. ( Abdou, AM; Fouda, IM; Fouda, UM; Ramadan, DI; Sayed, AM; Zaki, MM, 2011) |
| "Between August 1 2000 and June 20 2007, 116 pregnant women with: (i) | 5.14 | Dalteparin for the prevention of recurrence of placental-mediated complications of pregnancy in women without thrombophilia: a pilot randomized controlled trial. ( David, M; Demers, C; Garneau, P; Gauthier, R; Kahn, SR; Leduc, L; Magee, LA; Michon, N; Morin, F; Rey, E; Rodger, M, 2009) |
| "To compare the effect of aspirin and enoxaparin on live births in women with unexplained recurrent miscarriages, as well as secondary outcomes including birth weight, uterine and umbilical blood flows, and congenital malformations." | 5.12 | A randomized study of thromboprophylaxis in women with unexplained consecutive recurrent miscarriages. ( Brenner, B; Carp, H; Dolitzky, M; Inbal, A; Segal, Y; Weiss, A, 2006) |
| "To compare low molecular weight heparin (LMWH), specifically dalteparin, to unfractionated heparin (UFH) for the treatment of antiphospholipid antibody syndrome (APS) in pregnancy." | 5.11 | Treatment of antiphospholipid antibody syndrome (APS) in pregnancy: a randomized pilot trial comparing low molecular weight heparin to unfractionated heparin. ( Ballem, PJ; Ensom, MH; Ensworth, S; Houlihan, E; Purkiss, S; Stephenson, MD; Tsang, P, 2004) |
| " In a randomised open study, 44 pregnant women with confirmed previous or current thromboembolism were randomised to receive either low-molecular-weight heparin, dalteparin (N = 21) once daily subcutaneously or unfractionated sodium heparin (UF heparin, N = 23) twice daily subcutaneously for thromboprophylaxis during pregnancy and puerperium." | 5.10 | Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin. ( Hiilesmaa, V; Kaaja, R; Leinonen, P; Markkola, A; Pettilä, V, 2002) |
| "Literature on the efficacy and safety of enoxaparin for thromboembolism and thromboprophylaxis remains scanty, and therefore efficacy was not assessed; in terms of safety, when including other indications for enoxaparin in pregnancy, we found that enoxaparin was associated with significantly lower complications than aspirin." | 5.05 | Safety and Efficacy of Enoxaparin in Pregnancy: A Systematic Review and Meta-Analysis. ( Jacobson, B; Leisegang, R; Naidoo, P; Paek, D; Rambiritch, V; Sayre, T; Shan, J, 2020) |
| " Low dose aspirin should be given to every pregnant woman with antiphospholipid antibodies, with the addition of low molecular weight heparin in those with previous thrombosis, previous fetal death or failure of monotherapy with aspirin." | 4.85 | [The antiphospholipid syndrome in the 21st century]. ( Egurbide, MV; Martinez-Berriotxoa, A; Ruiz-Irastorza, G, 2009) |
| "The present study suggests that pravastatin may improve pregnancy outcomes in women with refractory obstetric APS when taken at the onset of PE or IUGR until the end of pregnancy." | 3.83 | Pravastatin improves pregnancy outcomes in obstetric antiphospholipid syndrome refractory to antithrombotic therapy. ( Dagklis, T; Girardi, G; Lefkou, E; Mamopoulos, A; Rousso, D; Vosnakis, C, 2016) |
| "The aim of this retrospective, observational study was to determine the impact of low-dose enoxaparin (20 mg) in conjunction with low-dose aspirin on the pregnancy outcome of women with antiphospholipid syndrome and recurrent miscarriage." | 3.75 | Treatment of recurrent miscarriage and antiphospholipid syndrome with low-dose enoxaparin and aspirin. ( Li, TC; Makris, M; Metwally, M; Mo, D; Saravelos, S, 2009) |
| "Dalteparin sodium injection in patients with an immunologic component to RPL resulted in an increase in compliance without any adverse early pregnancy outcomes." | 3.70 | Dalteparin sodium injection treatment in patients with immunologic recurrent pregnancy loss. ( Trott, AM; Trott, EA, 2000) |
| "To compare two enoxaparin dosing strategies at achieving prophylactic anti-Xa levels in women with a body mass index (BMI) ⩾35 (kg m(-2)) postcesarean delivery." | 2.82 | A randomized controlled trial of differing doses of postcesarean enoxaparin thromboprophylaxis in obese women. ( Caballero, DC; McNulty, J; Neeper, JM; Serra, AE; Stephenson, ML, 2016) |
| " We used American College of Obstetrics and Gynecology recommendations as the base for screening and dosing guidelines and utilized known and published absolute risk values and odds ratios to stratify risk factors." | 2.61 | Risk Assessment and Treatment Guide for Obstetric Thromboprophylaxis: Comprehensive Review of Current Guidelines. ( Deering, SH; Eubanks, AA; Thiel, LM, 2019) |
| "The authors report a pregnancy with fetal growth restriction at 36 weeks in a 31-year-old primigravida with symptomatic BD, treated with uninterrupted monthly IFX and daily enoxaparin." | 2.50 | Pregnancy management in Behçet's disease treated with uninterrupted infliximab. Report of a case with fetal growth restriction and mini-review of the literature. ( Correa, R; De Franciscis, P; Della Gala, A; Di Donna, MC; Ercolano, S; Esposito, E; Mainini, G; Stradella, L, 2014) |
| "Women with thrombophilia have an increased risk of pregnancy loss and possibly other serious obstetric complications, although definition of the magnitude of risk will require prospective longitudinal studies." | 2.42 | Thrombophilia and pregnancy complications. ( Kujovich, JL, 2004) |
| "Dalteparin is a low molecular weight heparin (LMWH) with a mean molecular weight of 5000." | 2.41 | Dalteparin: an update of its pharmacological properties and clinical efficacy in the prophylaxis and treatment of thromboembolic disease. ( Dunn, CJ; Jarvis, B, 2000) |
| " The enhanced bioavailability of these drugs, in conjunction with their prolonged half-life, makes subcutaneous therapy, in one to two daily doses, possible." | 2.39 | Low molecular weight heparins and their use in obstetrics and gynecology. ( Fejgin, MD; Lourwood, DL, 1994) |
| "Human pregnancy is associated with a mild proinflammatory state characterized by circulatory neutrophil activation which is further increased in complicated pregnancies, placenta-mediated complications being associated with an increased thrombotic risk." | 1.62 | NETosis Markers in Pregnancy: Effects Differ According to Histone Subtypes. ( Bouvier, S; Demattei, C; Fortier, M; Gris, JC; Herzog, M; Letouzey, V; Mercier, E; Mousty, E; Nouvellon, E; Rommelaere, G; Vincent, L, 2021) |
| " There is limited evidence to support current dosing and monitoring strategies of enoxaparin in this population." | 1.43 | Evaluation of therapeutic enoxaparin in a pregnant population at a tertiary hospital. ( Allen, J; Barras, M; Fagermo, N; Lust, K; Martin, JH; Petrie, S, 2016) |
| "To compare the adequacy of venous thromboembolism prophylaxis based on anti-Xa concentrations between weight-based enoxaparin dosing and body mass index (BMI)-stratified dosing in morbidly obese women after cesarean delivery." | 1.42 | Enoxaparin dosing after cesarean delivery in morbidly obese women. ( LaCoursiere, DY; Overcash, RT; Somers, AT, 2015) |
| "The incidence of severe pregnancy complications in previous pregnancies was similar in both groups." | 1.37 | Low molecular weight heparin treatment during subsequent pregnancies of women with inherited thrombophilia and previous severe pregnancy complications. ( Gamzu, R; Kupferminc, MJ; Lessing, JB; Many, A; Rimon, E; Sharon, M, 2011) |
| "Intravenous magnesium sulfate for seizure prophylaxis and oxytocin for induction of labor were started." | 1.35 | Systemic lupus erythematosus presenting with leukocytoclastic vasculitis and seizure during pregnancy. ( Borahay, MA; Harirah, HM; Kelly, BC, 2009) |
| " The results of this study indicate that nadroparin alone is useful and safe in the management of pregnant patients with APS." | 1.33 | Efficacy and safety of nadroparin in the treatment of pregnant women with antiphospholipid syndrome: a prospective cohort study. ( Chiarelli, S; De Silvestro, G; Fais, G; Favaro, M; Pengo, V; Ruffatti, A; Suma, V; Todesco, S; Tonello, M, 2005) |
| "Subchorionic hematoma is a potentially serious complication that can occur in pregnant patients receiving enoxaparin for the prevention of thromboembolism." | 1.33 | Massive subchorionic hematoma associated with enoxaparin. ( Goodwin, TM; Lee, RH, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (9.09) | 18.2507 |
| 2000's | 26 (47.27) | 29.6817 |
| 2010's | 20 (36.36) | 24.3611 |
| 2020's | 4 (7.27) | 2.80 |
| Authors | Studies |
|---|---|
| Ruffatti, A | 2 |
| Favaro, M | 2 |
| Tonello, M | 2 |
| De Silvestro, G | 2 |
| Pengo, V | 2 |
| Fais, G | 1 |
| Suma, V | 1 |
| Chiarelli, S | 1 |
| Todesco, S | 1 |
| Marson, P | 1 |
| Bortolati, M | 1 |
| Minucci, D | 1 |
| Stojanovich, L | 1 |
| Mikovic, Z | 1 |
| Mandic, V | 1 |
| Popovich-Kuzmanovich, D | 1 |
| Arnout, J | 1 |
| Spitz, B | 1 |
| Wittevrongel, C | 1 |
| Vanrusselt, M | 1 |
| Van Assche, A | 1 |
| Vermylen, J | 1 |
| Karag'ozova, Zh | 1 |
| Chernev, T | 1 |
| Iankova, Z | 1 |
| Baleva, M | 1 |
| Dimitrov, A | 1 |
| San Juan Alvarez, M | 1 |
| Márquez Garrido, G | 1 |
| Rodríguez Bertos, C | 1 |
| González Pérez, L | 1 |
| Grandone, E | 1 |
| Martinelli, P | 1 |
| Villani, M | 1 |
| Vecchione, G | 1 |
| Fischetti, L | 1 |
| Leccese, A | 1 |
| Santacroce, R | 1 |
| Corso, G | 1 |
| Margaglione, M | 1 |
| Rottenstreich, A | 1 |
| Gershgoren, H | 1 |
| Spectre, G | 1 |
| Da'as, N | 1 |
| Bentur, OS | 1 |
| Levin, G | 1 |
| Kalish, Y | 1 |
| Jacobson, B | 1 |
| Rambiritch, V | 1 |
| Paek, D | 1 |
| Sayre, T | 1 |
| Naidoo, P | 1 |
| Shan, J | 1 |
| Leisegang, R | 1 |
| Bouvier, S | 2 |
| Fortier, M | 1 |
| Vincent, L | 1 |
| Demattei, C | 1 |
| Mousty, E | 1 |
| Herzog, M | 1 |
| Rommelaere, G | 1 |
| Nouvellon, E | 1 |
| Mercier, E | 2 |
| Letouzey, V | 1 |
| Gris, JC | 3 |
| Farooqui, AB | 1 |
| Humbert, ML | 1 |
| Montague, MS | 1 |
| Doré, S | 1 |
| Simpkins, AN | 1 |
| Ozturk, G | 1 |
| Akpinar, P | 1 |
| Karamanlioglu, AD | 1 |
| Ozkan, FU | 1 |
| Aktas, I | 1 |
| Eubanks, AA | 1 |
| Deering, SH | 1 |
| Thiel, LM | 1 |
| Schaal, JV | 1 |
| Benhamou, D | 1 |
| Boyer, K | 1 |
| Mercier, FJ | 1 |
| Cochery-Nouvellon, E | 1 |
| Lavigne-Lissalde, G | 1 |
| Marchetti, T | 1 |
| Balducchi, JP | 1 |
| Marès, P | 2 |
| Mainini, G | 1 |
| Di Donna, MC | 1 |
| Esposito, E | 1 |
| Ercolano, S | 1 |
| Correa, R | 1 |
| Stradella, L | 1 |
| Della Gala, A | 1 |
| De Franciscis, P | 1 |
| Martí-Gamboa, S | 1 |
| Savirón Cornudella, R | 1 |
| Campillos-Maza, JM | 1 |
| Pasquier, E | 1 |
| de Saint Martin, L | 1 |
| Bohec, C | 1 |
| Chauleur, C | 1 |
| Bretelle, F | 1 |
| Marhic, G | 1 |
| Le Gal, G | 1 |
| Debarge, V | 1 |
| Lecomte, F | 1 |
| Denoual-Ziad, C | 1 |
| Lejeune-Saada, V | 1 |
| Douvier, S | 1 |
| Heisert, M | 1 |
| Mottier, D | 1 |
| Rodger, MA | 1 |
| Overcash, RT | 1 |
| Somers, AT | 1 |
| LaCoursiere, DY | 1 |
| Stephenson, ML | 1 |
| Serra, AE | 1 |
| Neeper, JM | 1 |
| Caballero, DC | 1 |
| McNulty, J | 1 |
| Petrie, S | 1 |
| Barras, M | 1 |
| Lust, K | 1 |
| Fagermo, N | 1 |
| Allen, J | 1 |
| Martin, JH | 1 |
| Lefkou, E | 1 |
| Mamopoulos, A | 1 |
| Dagklis, T | 1 |
| Vosnakis, C | 1 |
| Rousso, D | 1 |
| Girardi, G | 1 |
| Fernández-Alba, JJ | 1 |
| González-Macías, C | 1 |
| Vilar Sánchez, A | 1 |
| Tajada Cepero, P | 1 |
| Garrido Teruel, R | 1 |
| García-Cabanillas, MJ | 1 |
| Moreno-Corral, LJ | 1 |
| Torrejón Cardoso, R | 1 |
| Demers, S | 1 |
| Bujold, E | 1 |
| Roberge, S | 1 |
| Alijotas-Reig, J | 1 |
| Casellas-Caro, M | 1 |
| Ferrer-Oliveras, R | 1 |
| Llurba-Olive, E | 1 |
| Hermosilla, E | 1 |
| Vilardell-Tarres, M | 1 |
| Cabero-Roura, L | 1 |
| Borahay, MA | 1 |
| Kelly, BC | 1 |
| Harirah, HM | 1 |
| Ruiz-Irastorza, G | 1 |
| Martinez-Berriotxoa, A | 1 |
| Egurbide, MV | 1 |
| Mo, D | 1 |
| Saravelos, S | 1 |
| Metwally, M | 1 |
| Makris, M | 1 |
| Li, TC | 1 |
| Jerzak, M | 1 |
| Niemiec, T | 1 |
| Nowakowska, A | 1 |
| Klochowicz, M | 1 |
| Górski, A | 1 |
| Baranowski, W | 1 |
| Kupferminc, MJ | 1 |
| Rimon, E | 1 |
| Many, A | 3 |
| Sharon, M | 1 |
| Lessing, JB | 1 |
| Gamzu, R | 1 |
| Fouda, UM | 1 |
| Sayed, AM | 1 |
| Abdou, AM | 1 |
| Ramadan, DI | 1 |
| Fouda, IM | 1 |
| Zaki, MM | 1 |
| Blickstein, D | 1 |
| Hod, M | 1 |
| Bar, J | 2 |
| Kujovich, JL | 1 |
| Gaiser, RR | 1 |
| Berkowitz, DH | 1 |
| Chou, D | 1 |
| Boedeker, CC | 1 |
| Ridder, GJ | 1 |
| Weerda, N | 1 |
| Maier, W | 1 |
| Klenzner, T | 1 |
| Schipper, J | 1 |
| Brenner, B | 2 |
| Ellis, M | 1 |
| Yarom, I | 1 |
| Yohai, D | 1 |
| Samueloff, A | 1 |
| Dolitzky, M | 1 |
| Inbal, A | 1 |
| Segal, Y | 1 |
| Weiss, A | 1 |
| Carp, H | 1 |
| Lee, RH | 1 |
| Goodwin, TM | 1 |
| Fejgin, MD | 1 |
| Lourwood, DL | 1 |
| Phillips, JK | 1 |
| Majumdar, G | 1 |
| Hunt, BJ | 2 |
| Savidge, GF | 1 |
| Dulitzki, M | 2 |
| Pauzner, R | 2 |
| Langevitz, P | 2 |
| Pras, M | 1 |
| Schiff, E | 1 |
| Bagga, R | 1 |
| Sawhney, H | 1 |
| Saxena, SV | 1 |
| Aggarwal, N | 1 |
| Vasishta, K | 1 |
| Ellison, J | 1 |
| Thomson, AJ | 1 |
| Conkie, JA | 1 |
| McCall, F | 1 |
| Walker, D | 1 |
| Greer, A | 1 |
| Livneh, A | 1 |
| Kenett, R | 1 |
| Vanderbeke, I | 1 |
| Boll, D | 1 |
| Verguts, JK | 1 |
| Rey, E | 1 |
| Garneau, P | 1 |
| David, M | 1 |
| Gauthier, R | 1 |
| Leduc, L | 1 |
| Michon, N | 1 |
| Morin, F | 1 |
| Demers, C | 1 |
| Kahn, SR | 1 |
| Magee, LA | 1 |
| Rodger, M | 1 |
| Henrich, W | 1 |
| Onügören, O | 1 |
| Kivelitz, D | 1 |
| Dudenhausen, JW | 1 |
| Stone, S | 1 |
| Seed, PT | 1 |
| Parmar, K | 1 |
| Khamashta, MA | 1 |
| Poston, L | 1 |
| Stephenson, MD | 1 |
| Ballem, PJ | 1 |
| Tsang, P | 1 |
| Purkiss, S | 1 |
| Ensworth, S | 1 |
| Houlihan, E | 1 |
| Ensom, MH | 1 |
| Shefras, J | 1 |
| Farquharson, RG | 1 |
| Trott, EA | 1 |
| Trott, AM | 1 |
| Dunn, CJ | 1 |
| Jarvis, B | 1 |
| Pettilä, V | 1 |
| Leinonen, P | 1 |
| Markkola, A | 1 |
| Hiilesmaa, V | 1 |
| Kaaja, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Essai thérapeutique randomisé Multicentrique en Double Insu, Comparant l'énoxaparine 40mg Versus Placebo, en Une Injection Sous-cutanée Quotidienne, Dans Les Fausses Couches spontanées récurrentes inexpliquées[NCT00740545] | Phase 3 | 258 participants (Actual) | Interventional | 2007-04-30 | Terminated (stopped due to Stopped for futility) | ||
| Comparing Anti-XA Levels in Post-Cesarean Patients With BMI >35 Undergoing Enoxaparin Thromboprophylaxis With Weight Based Dosing Twice Daily Versus Fixed Dose 40 Milligrams Daily[NCT02070237] | Phase 1 | 90 participants (Actual) | Interventional | 2013-08-31 | Completed | ||
| Low-molecular-weight Heparin Versus Unfractionated Heparin in Pregnant Women With History of Recurrent Abortion Secondary to Antiphospholipid Syndrome. A Randomized Controlled Trial[NCT01051778] | Phase 2 | 60 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| Effects of UFH and LMWH on Osteoprotegerin and RANKL Plasma Levels in Hemodialysis Patients[NCT00669721] | 40 participants (Anticipated) | Interventional | 2008-03-31 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Our primary outcome will be to assess the Anti Xa level drawn 3.5-4 hours after the third dose of Lovenox (enoxaparin) to assess if this is in the prophylactic range. (NCT02070237)
Timeframe: 3.5-4 hours after the third dose of Lovenox (enoxaparin)
| Intervention | IU/mL (Mean) |
|---|---|
| Enoxaparin Once Daily | 0.14 |
| Enoxaparin Twice Daily | 0.30 |
We will assess if any of the subjects has an Anti Xa level that is in the supraprophylactic range (treatment range). (NCT02070237)
Timeframe: 3.5-4 hours after the third dose of Lovenox (enoxaparin)
| Intervention | participants (Number) |
|---|---|
| Enoxaparin Once Daily | 0 |
| Enoxaparin Twice Daily | 0 |
Live birth occurs when a fetus (> 24 weeks ) , exits the maternal body and subsequently shows signs of life, such as voluntary movement, heartbeat, or pulsation of the umbilical cord. (NCT01051778)
Timeframe: pregnancy > 24weeks gestation
| Intervention | Percentage of pregnancies (Number) |
|---|---|
| Enoxaparin 40 mg /Day Plus Low Dose Aspirin | 24 |
| Heparin Calcium 5,000 U Twice Daily Plus Low Dose Aspirin | 20 |
10 reviews available for dalteparin and Complications, Pregnancy
| Article | Year |
|---|---|
Plasma exchange in the management of high risk pregnant patients with primary antiphospholipid syndrome. A report of 9 cases and a review of the literature.
Topics: Adult; Anticoagulants; Antiphospholipid Syndrome; Female; Humans; Immunoglobulins, Intravenous; Nadr | 2007 |
[Application of low-molecular-weight heparin during pregnancy and delivery in case of reproductive failure due to antiphospholipid syndrome].
Topics: Adult; Antiphospholipid Syndrome; Blood Coagulation; Cesarean Section; Female; Heparin, Low-Molecula | 2000 |
Safety and Efficacy of Enoxaparin in Pregnancy: A Systematic Review and Meta-Analysis.
Topics: Anticoagulants; Aspirin; Enoxaparin; Female; Hemorrhage; Humans; Pregnancy; Pregnancy Complications; | 2020 |
Risk Assessment and Treatment Guide for Obstetric Thromboprophylaxis: Comprehensive Review of Current Guidelines.
Topics: Anticoagulants; Enoxaparin; Female; Heparin; Humans; Postpartum Period; Practice Guidelines as Topic | 2019 |
Pregnancy management in Behçet's disease treated with uninterrupted infliximab. Report of a case with fetal growth restriction and mini-review of the literature.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Anticoagulants; Behcet Syndrome; En | 2014 |
[Massive gestational vulvar edema. A case report and review of literature].
Topics: Albumins; Anti-Infective Agents; Anticoagulants; Cesarean Section; Edema; Enoxaparin; Exudates and T | 2014 |
[The antiphospholipid syndrome in the 21st century].
Topics: Adult; Antibodies, Anticardiolipin; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Clinical Tri | 2009 |
Thrombophilia and pregnancy complications.
Topics: Abortion, Habitual; Enoxaparin; Factor V; Female; Fetal Growth Retardation; Fibrinolytic Agents; Hum | 2004 |
Low molecular weight heparins and their use in obstetrics and gynecology.
Topics: Clinical Trials as Topic; Enoxaparin; Female; Fetus; Gynecology; Hemorrhage; Heparin, Low-Molecular- | 1994 |
Dalteparin: an update of its pharmacological properties and clinical efficacy in the prophylaxis and treatment of thromboembolic disease.
Topics: Blood Coagulation; Coronary Disease; Dalteparin; Drug Costs; Drug Interactions; Economics, Pharmaceu | 2000 |
9 trials available for dalteparin and Complications, Pregnancy
| Article | Year |
|---|---|
Enoxaparin for prevention of unexplained recurrent miscarriage: a multicenter randomized double-blind placebo-controlled trial.
Topics: Abortion, Habitual; Adult; Anticoagulants; Double-Blind Method; Enoxaparin; Female; Follow-Up Studie | 2015 |
A randomized controlled trial of differing doses of postcesarean enoxaparin thromboprophylaxis in obese women.
Topics: Adult; Blood Coagulation; Body Mass Index; Chemoprevention; Dose-Response Relationship, Drug; Drug A | 2016 |
Enoxaparin versus unfractionated heparin in the management of recurrent abortion secondary to antiphospholipid syndrome.
Topics: Abortion, Habitual; Adult; Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; | 2011 |
A randomized study of thromboprophylaxis in women with unexplained consecutive recurrent miscarriages.
Topics: Abortion, Habitual; Abortion, Induced; Adult; Anticoagulants; Aspirin; Birth Rate; Birth Weight; Eno | 2006 |
Thromboprophylaxis following caesarean section--a comparison of the antithrombotic properties of three low molecular weight heparins--dalteparin, enoxaparin and tinzaparin.
Topics: Adolescent; Adult; Anticoagulants; Antithrombin III; Cesarean Section; Dalteparin; Enoxaparin; Facto | 2001 |
Low molecular weight heparin and warfarin in the treatment of patients with antiphospholipid syndrome during pregnancy.
Topics: Abnormalities, Drug-Induced; Adult; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Autoimmune D | 2001 |
Dalteparin for the prevention of recurrence of placental-mediated complications of pregnancy in women without thrombophilia: a pilot randomized controlled trial.
Topics: Adult; Dalteparin; Female; Fetal Death; Humans; Infant, Low Birth Weight; Infant, Newborn; Pilot Pro | 2009 |
Treatment of antiphospholipid antibody syndrome (APS) in pregnancy: a randomized pilot trial comparing low molecular weight heparin to unfractionated heparin.
Topics: Adult; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Dalteparin; Female; Heparin; Humans; Pilo | 2004 |
Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin.
Topics: Absorptiometry, Photon; Adult; Anticoagulants; Bone Density; Dalteparin; Factor Xa Inhibitors; Femal | 2002 |
36 other studies available for dalteparin and Complications, Pregnancy
| Article | Year |
|---|---|
Efficacy and safety of nadroparin in the treatment of pregnant women with antiphospholipid syndrome: a prospective cohort study.
Topics: Adult; Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Female; Follow-Up St | 2005 |
Treatment of antiphospholipid syndrome in pregnancy with low doses of intravenous immunoglobulin.
Topics: Adult; Anti-Inflammatory Agents; Antiphospholipid Syndrome; Autoantibodies; Dexamethasone; Dose-Resp | 2007 |
High-dose intravenous immunoglobulin treatment of a pregnant patient with an antiphospholipid syndrome: immunological changes associated with a successful outcome.
Topics: Adult; Antibodies, Anti-Idiotypic; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Aspirin; | 1994 |
[Hip fracture during pregancy in a woman with transient osteporosis].
Topics: Accidental Falls; Adult; Anticoagulants; Bone Screws; Cesarean Section; Female; Fracture Fixation, I | 2010 |
Prospective evaluation of pregnancy outcome in an Italian woman with late-onset combined homocystinuria and methylmalonic aciduria.
Topics: Abortion, Spontaneous; Adult; Anticoagulants; Enoxaparin; Female; Fetal Growth Retardation; Homocyst | 2019 |
Factors associated with pregnancy outcomes in women with a history of cerebral sinus venous thrombosis.
Topics: Abortion, Spontaneous; Abruptio Placentae; Adult; Anticoagulants; Case-Control Studies; Enoxaparin; | 2020 |
NETosis Markers in Pregnancy: Effects Differ According to Histone Subtypes.
Topics: Adult; Apoptosis; Aspirin; Cell Line; Cell Movement; Enoxaparin; Extracellular Traps; Female; France | 2021 |
Cerebral Venous Thrombosis and Hypercoagulability Associated With In Vitro Fertilization.
Topics: Adult; Anticoagulants; Enoxaparin; Female; Fertilization in Vitro; Humans; Intracranial Thrombosis; | 2021 |
Pregnancy-related osteoporotic vertebral compression fractures in two patients treated with low-molecular-weight heparin during pregnancy: case reports.
Topics: Absorptiometry, Photon; Adult; Anticoagulants; Bone Density; Enoxaparin; Female; Fractures, Compress | 2018 |
[Parkes-Weber syndrome and pregnancy: anaesthetic implications].
Topics: Adult; Analgesia, Epidural; Analgesia, Obstetrical; Anticoagulants; Arteriovenous Malformations; Emb | 2013 |
Comparative incidence of pregnancy outcomes in treated obstetric antiphospholipid syndrome: the NOH-APS observational study.
Topics: Abortion, Habitual; Abortion, Spontaneous; Adolescent; Adult; Antibodies, Anticardiolipin; Antibodie | 2014 |
Recurrent pregnancy loss: drop the heparin needles….
Topics: Abortion, Habitual; Enoxaparin; Female; Humans; Pregnancy; Pregnancy Complications | 2015 |
Enoxaparin dosing after cesarean delivery in morbidly obese women.
Topics: Adult; Anticoagulants; Body Mass Index; Body Weight; Cesarean Section; Drug Dosage Calculations; Dru | 2015 |
Evaluation of therapeutic enoxaparin in a pregnant population at a tertiary hospital.
Topics: Adolescent; Adult; Anticoagulants; Dose-Response Relationship, Drug; Drug Monitoring; Enoxaparin; Fe | 2016 |
Pravastatin improves pregnancy outcomes in obstetric antiphospholipid syndrome refractory to antithrombotic therapy.
Topics: Adult; Antiphospholipid Syndrome; Endothelium; Enoxaparin; Female; Fibrinolytic Agents; Gestational | 2016 |
Birthweight in pregnant women with protein S deficiency treated with low-molecular-weight heparin: a retrospective cohort study.
Topics: Adult; Anticoagulants; Birth Weight; Case-Control Studies; Enoxaparin; Female; Fetal Growth Retardat | 2017 |
Enoxaparin and Aspirin Compared With Aspirin Alone to Prevent Placenta-Mediated Pregnancy Complications: A Randomized Controlled Trial.
Topics: Anticoagulants; Aspirin; Enoxaparin; Female; Humans; Placenta; Platelet Aggregation Inhibitors; Preg | 2017 |
Are anti-beta-glycoprotein-I antibodies markers for recurrent pregnancy loss in lupus anticoagulant/anticardiolipin seronegative women?
Topics: Abortion, Habitual; Adult; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Anticoagulants | 2008 |
Systemic lupus erythematosus presenting with leukocytoclastic vasculitis and seizure during pregnancy.
Topics: Antibodies, Antinuclear; Anticoagulants; Enoxaparin; Female; Glucocorticoids; Humans; Intracranial T | 2009 |
Treatment of recurrent miscarriage and antiphospholipid syndrome with low-dose enoxaparin and aspirin.
Topics: Abortion, Habitual; Adult; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Dose-Response Relatio | 2009 |
First successful pregnancy after addition of enoxaparin to sildenafil and etanercept immunotherapy in woman with fifteen failed IVF cycles - case report.
Topics: Anticoagulants; Cytotoxicity, Immunologic; Drug Therapy, Combination; Endometriosis; Enoxaparin; Eta | 2010 |
Low molecular weight heparin treatment during subsequent pregnancies of women with inherited thrombophilia and previous severe pregnancy complications.
Topics: Adult; Anticoagulants; Enoxaparin; Female; Humans; Pregnancy; Pregnancy Complications; Pregnancy Com | 2011 |
Eczematous plaques related to unfractionated and low-molecular-weight heparin in pregnancy: cross-reaction with danaparoid sodium.
Topics: Adult; Aspirin; Chondroitin Sulfates; Dalteparin; Dermatan Sulfate; Drug Combinations; Drug Therapy, | 2003 |
Epidural blood patch in a patient taking enoxaparin.
Topics: Adult; Blood Patch, Epidural; Enoxaparin; Factor V; Female; Headache; Hematoma, Epidural, Spinal; Hu | 2004 |
[Etiology and therapy of the internal jugular vein thrombosis].
Topics: Administration, Oral; Adult; Aged; Anti-Bacterial Agents; Cefuroxime; Cellulitis; Diagnosis, Differe | 2004 |
Effects of enoxaparin on late pregnancy complications and neonatal outcome in women with recurrent pregnancy loss and thrombophilia: results from the Live-Enox study.
Topics: Abortion, Habitual; Enoxaparin; Female; Humans; Infant, Newborn; Live Birth; Pregnancy; Pregnancy Co | 2005 |
Massive subchorionic hematoma associated with enoxaparin.
Topics: Adult; Anticoagulants; Atrial Fibrillation; Cesarean Section; Chorion; Enoxaparin; Factor Xa Inhibit | 2006 |
Heparin-induced skin reaction due to two different preparations of low molecular weight heparin (LMWH)
Topics: Adult; Dalteparin; Drug Eruptions; Enoxaparin; Erythema; Female; Femoral Vein; Humans; Iliac Vein; P | 1993 |
Low-molecular-weight heparin during pregnancy and delivery: preliminary experience with 41 pregnancies.
Topics: Adult; Antiphospholipid Syndrome; Enoxaparin; Female; Fibrinolytic Agents; Humans; Labor, Obstetric; | 1996 |
Intracranial bleed in a pregnant patient on oral anticoagulants for prosthetic heart valve.
Topics: Acenocoumarol; Adult; Anticoagulants; Aortic Valve; Enoxaparin; Female; Heart Valve Prosthesis; Huma | 2001 |
[Pregnancy and childbirth in a patient with a spinal cord lesion].
Topics: Adult; Dalteparin; Delivery, Obstetric; Female; Humans; Infant, Newborn; Labor, Obstetric; Male; Pre | 2008 |
Transvaginal color Doppler for the visualization of pelvic vein thrombosis during pregnancy.
Topics: Adult; Anticoagulants; Dalteparin; Female; Humans; Iliac Vein; Pregnancy; Pregnancy Complications; T | 2009 |
Heparin promotes soluble vascular enothelial growth factor receptor expression in human placental villi: a rebuttal.
Topics: Chorionic Villi; Dalteparin; Endothelium, Vascular; Female; Heparin, Low-Molecular-Weight; Humans; P | 2012 |
Longitudinal evaluation of markers of endothelial cell dysfunction and hemostasis in treated antiphospholipid syndrome and in healthy pregnancy.
Topics: Anticoagulants; Antiphospholipid Syndrome; Aspirin; Biomarkers; Dalteparin; Endothelium, Vascular; F | 2003 |
Bone density studies in pregnant women receiving heparin.
Topics: Anticoagulants; Antiphospholipid Syndrome; Bone Density; Case-Control Studies; Dalteparin; Female; H | 1996 |
Dalteparin sodium injection treatment in patients with immunologic recurrent pregnancy loss.
Topics: Abortion, Habitual; Adult; Anticoagulants; Dalteparin; Female; Humans; Injections, Subcutaneous; Pre | 2000 |